Abstract
A pro-drug is a substance administered in a pharmacologically inactive structure that, once administered, is metabolised in vivo into the corresponding active principle. The rationale for the design of prodrugs is the optimisation of absorption, distribution, metabolism, and excretion (ADME). Moreover these compounds are frequently synthesized to improve bioavailability. 5-Amino salicylic acid (5-ASA) represents one of the most efficient agents for ColoRectal Cancer (CRC) treatment. Its inclusion in natural or semi-synthetic cyclodextrins (CDs) has been extensively studied to enhance drug properties as solubility, stability, and bioavailability. On the other hand, very recently naturally occurring 4'-geranyloxyferulic acid and auraptene were found as novel promising agents for the treatment of colon diseases, like adenomas and adenocarcinomas. In this review we will focus our attention on the reported pharmacological activity and analytical assays for the most representative 5-ASA pro-drugs already in a therapy for the treatment of CRC and on novel prodrugs of 4'-geranyloxyferulic acid and auraptene that were shown to be efficient in vivo as dietary feeding colon cancer chemopreventers in mice.
Keywords: CRC, IBD, inclusion compounds, 4'-geranyloxyferulic acid, auraptene, biological activity, analytical method, HPLC-UV/Vis methodologies, pro-drug, b-cyclodextrin
Current Drug Delivery
Title: Novel Prodrugs for the Treatment of Colonic Diseases Based on 5-Aminosalicylic Acid, 4'-eranyloxyferulic Acid, and Auraptene: Biological Activities and Analytical Assays
Volume: 9 Issue: 2
Author(s): Francesco Epifano, Salvatore Genovese, Giuseppe Carlucci and Marcello Locatelli
Affiliation:
Keywords: CRC, IBD, inclusion compounds, 4'-geranyloxyferulic acid, auraptene, biological activity, analytical method, HPLC-UV/Vis methodologies, pro-drug, b-cyclodextrin
Abstract: A pro-drug is a substance administered in a pharmacologically inactive structure that, once administered, is metabolised in vivo into the corresponding active principle. The rationale for the design of prodrugs is the optimisation of absorption, distribution, metabolism, and excretion (ADME). Moreover these compounds are frequently synthesized to improve bioavailability. 5-Amino salicylic acid (5-ASA) represents one of the most efficient agents for ColoRectal Cancer (CRC) treatment. Its inclusion in natural or semi-synthetic cyclodextrins (CDs) has been extensively studied to enhance drug properties as solubility, stability, and bioavailability. On the other hand, very recently naturally occurring 4'-geranyloxyferulic acid and auraptene were found as novel promising agents for the treatment of colon diseases, like adenomas and adenocarcinomas. In this review we will focus our attention on the reported pharmacological activity and analytical assays for the most representative 5-ASA pro-drugs already in a therapy for the treatment of CRC and on novel prodrugs of 4'-geranyloxyferulic acid and auraptene that were shown to be efficient in vivo as dietary feeding colon cancer chemopreventers in mice.
Export Options
About this article
Cite this article as:
Epifano Francesco, Genovese Salvatore, Carlucci Giuseppe and Locatelli Marcello, Novel Prodrugs for the Treatment of Colonic Diseases Based on 5-Aminosalicylic Acid, 4'-eranyloxyferulic Acid, and Auraptene: Biological Activities and Analytical Assays, Current Drug Delivery 2012; 9 (2) . https://dx.doi.org/10.2174/156720112800234549
DOI https://dx.doi.org/10.2174/156720112800234549 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects
Current Bioinformatics Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine
Current Cancer Drug Targets Heterologous Expression and Characterization of Flavinadenine Dinucleotide Synthetase from <i>Candida famata</i> for Flavin Adenine Dinucleotide Production
Protein & Peptide Letters Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Erythropoietin in Cancer: An Update
Current Molecular Medicine Preclinical and Clinical Studies of Chidamide (CS055/HBI-8000), An Orally Available Subtype-selective HDAC Inhibitor for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety Urtica dioica Extract Inhibits Cell Proliferation and Induces Apoptosis in HepG2 and HTC116 as Gastrointestinal Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in New Discovered Molecular Targets in Testicular Germ Cell Tumors
Current Medicinal Chemistry The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders
Current Neuropharmacology VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1-Linked Functions Crosstalk
Protein & Peptide Letters ING Proteins as Potential Anticancer Drug Targets
Current Drug Targets Targeting Protein Degradation in Cancer Treatment
Current Chemical Biology Therapeutic Modulation of Gut Microbiota: Current Clinical Applications and Future Perspectives
Current Drug Targets Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology A Novel Approach to Anticancer Therapies: Peroxisome Proliferator Activator-Receptor-γ as a New Target Therapy in the Treatment of Human Urological Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression
Current Drug Targets Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases
Current Drug Metabolism Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics